Insider Cluster (2 insiders) ·Filed Sep 9, 2026

TRDA

Entrada Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed22d 16h ago
Insider cluster: 2 insiders, $547K total
Actionable Insight ▼ Bearish

The largest shareholder group is systematically reducing its stake with no insider buying to counterbalance. Monitor for additional MPM sales in coming weeks and any catalyst that might explain the exit — upcoming pipeline data or partnership news could be the driver. The selling is material enough to pressure the stock near-term.

DirectionBearish
Confidencemedium
Horizondays
Latest settled — T+5d
TRDA ▲ +7.48% at T+5d
SHORT call ✗ call lost -7.48% · α vs SPY -7.98% · entry $6.42 → $6.90
Next anchor: T+20d in 5d
Latest observation: T+12 +10.53% FF3 residual α
Entry anchored
Sep 9, 05:47 PM ET
via 1-min bar
T+1d
+5.92%
call -5.92% · α -5.07%
$6.80
settled 22d ago
T+5d
+7.48%
call -7.48% · α -7.98%
$6.90
settled 16d ago
T+20d
—
call — · α —
—
in 5d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Two MPM BioVentures funds (10% owners) sold a combined $547K in TRDA shares over two days, part of a larger 7-day cluster totaling $3.8M. The selling is concentrated at the largest shareholder level, not C-suite, and represents ~1.3% of market cap — a material reduction by a single insider group. No insider buying offsets this, and the pattern suggests systematic portfolio reduction rather than opportunistic timing.

Key Financial Metrics

Direction
selling
Total Value
$547.0K
Insiders
2

Key Facts

  • MPM BioVentures 2014 and 2018 funds sold 77,000 shares combined at $7.11 on 2026-09-04, totaling $547K
  • The same funds sold an additional $3.26M in TRDA on 2026-09-08 and 2026-09-09, bringing the 7-day cluster to $3.8M
  • Total 7-day selling represents ~1.3% of TRDA's $293M market cap
  • No insider purchases were reported in the cluster
  • All sales are open-market (Code S), not tax-withholding or derivative exercises

Financial Impact

$3.8M in open-market sales over 7 days, ~1.3% of market cap

dilutionownership concentration

Risk Factors

  • Continued selling by MPM BioVentures could further pressure the stock
  • No insider buying suggests management/board are not stepping in to signal confidence
  • Large shareholder exit may indicate negative non-public information about pipeline or financials

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TRDA-1788999611457
18 reports for TRDA
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +58.52%May 4, 2026
Filters
Rows
Reports for TRDA — sortable, filterable
TypeNow
Sep 9, 2026
22d ago
Insider Cluster
BEARISH ★ 6/10
$6.42 $6.90▼ −7.48%▼ −7.98%$5.21 (+18.85%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 3/10
$7.17 $6.80▼ −5.16%▼ −4.01%$5.21 (−27.34%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.21 (−26.31%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.21 (−26.31%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.07 $7.11▲ +0.57%▲ +0.48%$5.21 (−26.31%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.27 $7.17▼ −1.38%▼ −1.64%$5.21 (−28.34%)
Aug 10, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.04 $7.27▲ +3.27%▲ +3.67%$5.21 (−25.99%)
Aug 5, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$7.06 $7.67▲ +8.64%▲ +8.29%$5.21 (−26.20%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$7.24 $7.04▼ −2.76%▼ −2.66%$5.21 (−28.04%)
Jul 30, 2026
9w ago
144
BEARISH ★ 5/10
$6.79 $6.87▼ −1.18%▲ +2.33%$5.21 (+23.27%)
Showing 10 of 18

US Market Status

Market Open — Closes in 2h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Sep 10, 2026